Lucanthone was chosen as an APE1 inhibitor for several reasons: It is in a Phase I clinical trial for tumor radiotherapy, its side effects are almost negligible, and it can inhibit APE1 endonuclease activity without affecting its redox function. The gene discussed is APEX1; the disease is neoplasm.